Myriad Genetics, Inc. (MYGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN)

MYGN 6.565

-3.2%

Dec 23 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sim1 who wrote (2331)	1/30/2011 10:40:56 AM
From: Doctor Zeus	of 2355

Not necessarily a negative for MYGN 'Sanofi’s results and AstraZeneca’s trial halt in breast cancer are a “negative signal” for this family of drugs having a broad application in oncology, said Navid Malik' The key word is 'broad'. Sanofi went for a broader indication, whilst MYGN focus is only on the BRCA mutations. I believe the Abbott test will only focus on BRCA mutants. Moreover, the Sanofi trial is yet to be analysed to see if the BRCA mutants responded or not. If they did respond, it could turn out to be a net positive for MYGN!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next